L3VLUP
ProSign in

RLAY · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RLAYGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RLAY
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterRLAYGILD
Q3 20202 holders, $57m25 holders, $14.2bn
Q4 20204 holders, $23m27 holders, $13.4bn
Q1 20213 holders, $21m24 holders, $14.5bn
Q2 20212 holders, $18m18 holders, $14.9bn
Q3 20214 holders, $449m20 holders, $16.4bn
Q4 20214 holders, $515m20 holders, $16.8bn
Q1 20225 holders, $514m28 holders, $13.2bn
Q2 20224 holders, $16m26 holders, $13.6bn
Q3 20227 holders, $131m24 holders, $13.3bn
Q4 20223 holders, $16m32 holders, $21.1bn
Q1 20234 holders, $129m27 holders, $21.8bn
Q2 20233 holders, $8.6m24 holders, $20.7bn
Q3 20234 holders, $6.9m24 holders, $20.0bn
Q4 20234 holders, $12m22 holders, $21.5bn
Q1 20244 holders, $7.6m30 holders, $20.3bn
Q2 20244 holders, $5.8m28 holders, $18.5bn
Q3 20242 holders, $2.9m29 holders, $24.2bn
Q4 20241 holders, $447k28 holders, $25.9bn
Q1 20251 holders, $28m33 holders, $32.0bn
Q2 20251 holders, $47m27 holders, $30.9bn
Q3 20251 holders, $77m23 holders, $29.4bn
Q4 20253 holders, $127m25 holders, $34.3bn
Q1 2026none listed holders, n.a.25 holders, $38.5bn
Q2 20262 holders, $25m26 holders, $34.2bn
RLAY

Relay Therapeutics Inc

Holders
1
Reported value
$77m
Buyers
1
Sellers
0

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
23
Reported value
$29.4bn
Buyers
9
Sellers
14

Breadth -5 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2025

Among the 24 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only RLAY (1)

Point72 Asset Management LP

Only GILD (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →